Pharma Industry News

EMA PRIME status granted to Janssen’s inherited retinal disease gene therapy

The designation makes the drug the only XLRP treatment in development to be awarded PRIME designation.Original Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

[mwai_chat window="true" fullscreen="true"]